Navigation Links
NIAID announces vaccine adjuvant discovery contracts
Date:10/8/2009

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.

"The goal of these awards is to find safe new adjuvants that will boost the effectiveness of vaccines," says NIAID Director Anthony S. Fauci, M.D. "Adjuvants can be used not only to enhance the immune response to a vaccine and thereby offer better protection but also to extend the vaccine supply if needed, enabling more people to be vaccinated with fewer doses."

Currently, the only vaccine adjuvant approved for use in the United States is an aluminum mixture known as alum.

NIAID has awarded a total of approximately $60 million over five years for these contracts. The awardees will identify novel compounds with the potential to be vaccine adjuvants. All compounds will be tested in animal models and human cells to determine how well they stimulate the immune response. The investigators also will examine and describe the cellular reactions the compounds induce.

"The goal of these awards is not only to identify new adjuvant candidates but also to describe how these candidates work," says Helen Quill, Ph.D., chief of NIAID's basic immunology research branch. "We would hope that these adjuvant candidates will become part of a robust pipeline leading to the development of many different vaccines."

The awardees of the adjuvant contracts will work to identify and characterize novel adjuvants that trigger receptors of the inborn, or innate, immune system. These receptors recognize and bind small molecules that are unique to harmful microorganisms. Binding stimulates an immediate innate immune response, a broadly protective reaction. The innate immune response also is required for the development of the highly specific antibody and T-cell responses that characterize long-term immunity.

The investigators also will seek to identify the cellular receptor for each of the novel adjuvant candidates, determine how it triggers the innate immune response, and then make changes to the adjuvant to improve its ability to induce the innate immune response. Although a number of innate immune receptors already have been described, many more likely exist and are expected to be uncovered in the course of these projects.

"The award of these contracts is an integral part of NIAID's long-range plan to expand the adjuvant pipeline," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology, and Transplantation, which oversees these awards. "A first round of NIAID contracts, awarded in 2003, limited the discovery of novel adjuvants to those that stimulated the only group of innate immune receptors known at the time. With this second round of awards, we intend to increase the number of adjuvant candidates by expanding the research scope to include all known innate immune receptors."

The institutions receiving contracts for 2009 are

  • James R. Baker, Jr., M.D., University of Michigan, Ann Arbor
  • Dennis A. Carson, M.D., Moores Cancer Center, University of California San Diego, La Jolla
  • Sunil A. David, M.D., Ph.D., University of Kansas, Lawrence
  • Michael J. Gale, Jr., Ph.D., University of Washington School of Medicine, Seattle
  • David A. Johnson, Ph.D., Corixa Corporation (now part of GlaxoSmithKline Biologicals), Hamilton, Mont.
  • Peter Palese, Ph.D., Mount Sinai School of Medicine, New York City


'/>"/>

Contact: Julie Wu
wujuli@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
2. NIAID launches 2009 H1N1 influenza vaccine trial in pregnant women
3. NIAID funds clinical trials that address the problem of antimicrobial resistance
4. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
5. NIAID to fund new human immune profiling research centers
6. NIAID media availability: Still searching for predictors of asthma attacks
7. NIAID set to launch clinical trials to test 2009 H1N1 influenza vaccine candidates
8. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine
9. J. Craig Venter Institute Awarded $43 Million, Five Year Contract From NIAID to Continue to Develop and Provide Sequencing, Genotyping, and Bioinformatics Expertise and Services in Infectious Diseases
10. NIAID and Chinese officials sign agreement to foster TB research in Chinas Henan province
11. NIAID honors AIDS activist Martin Delaney
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career Step company, ... Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, ... be presented by Captain Rommie Duckworth, LP, a career fire captain as well as ...
(Date:5/24/2017)... ... May 24, 2017 , ... Rob Lowe is a ... developed for Public Television. “Informed” brings the public important topics from all aspects of ... of the feet and issues surrounding feet and ankles. , Podiatry is essential to ...
(Date:5/24/2017)... Shoreview, MN (PRWEB) , ... May 24, 2017 ... ... manufacturer of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had ... network now consists of a mix of domestic and rest of world (ROW) ...
(Date:5/23/2017)... NEW YORK, NY (PRWEB) , ... May 23, ... ... decision makers in the pharmaceutical and medical device sectors, today announced the winners ... • Transformers • Entrepreneurs) represent the most influential people in the healthcare industry ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... professionals, is pleased to announce the organization’s Certified Strength Coach credential has earned ... Strength Coach (CSC) program validates the competency of qualified candidates for jobs in ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke Awareness ... of the most important methods to prevent a stroke: ... Centers for Disease Control and Prevention, undetected and uncontrolled ... Omron, the global leader in personal heart health ... elimination of heart attack and stroke and is advancing ...
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
Breaking Medicine Technology: